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Abstract
Ovarian cancer affects more than 200,000 women each year around the world. Most women are
not diagnosed until the disease has already metastasized from the ovaries with a resultant poor
prognosis. Ovarian cancer is associated with an overall 5 year survival of little more than 50%. The
mainstay of front-line therapy is cytoreductive surgery followed by chemotherapy. Traditionally,
this has been by the intravenous route only but there is more interest in the delivery of
intraperitoneal chemotherapy utilizing the pharmaco-therapeutic advantage of the peritoneal
barrier. Despite three large, randomized clinical trials comparing intravenous with intraperitoneal
chemotherapy showing improved outcomes for those receiving at least part of their chemotherapy
by the intraperitoneal route.
Cisplatin has been the most active drug for the treatment of ovarian cancer for the last 4 decades
and the prognosis for women with ovarian cancer can be defined by the tumor response to
cisplatin. Those whose tumors are innately platinum-resistant at the time of initial treatment have
a very poor prognosis. Although the majority of patients with ovarian cancer respond to front-line
platinum combination chemotherapy the majority will develop disease that becomes resistant to
cisplatin and will ultimately succumb to the disease.
Improving the efficacy of cisplatin could have a major impact in the fight against this disease.
Arsenite is an exciting agent that not only has inherent single-agent tumoricidal activity against
ovarian cancer cell lines but also multiple biochemical interactions that may enhance the
cytotoxicity of cisplatin including inhibition of deoxyribose nucleic acid (DNA) repair. In vitro
studies suggest that arsenite may enhance the activity of cisplatin in other cell types. Arsenic
trioxide is already used clinically to treat acute promyelocytic leukemia demonstrating its safety
profile. Further research in ovarian cancer is warranted to define its possible role in this disease.
Review
Epithelial ovarian cancer (EOC) affects approximately
204,000 women a year worldwide and is responsible for
about 125,000 deaths [1]. The American Cancer Society
estimates that in the USA alone the disease will be diag-
nosed in 21,650 women and cause the death of 15,520
women during 2008 [2]. It is often called the 'silent killer'
because it causes few symptoms until it has metastasized
within the peritoneal cavity at which time the chance of
cure is markedly reduced. Although great strides have
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that a disease which is highly sensitive to chemotherapy
compared to many other types of cancer is associated with
an overall 5 year survival of just over 50% [3-6].
Cytoreductive Surgery
The management of advanced EOC has evolved over the
last 30 years to become a combination of initial cytore-
ductive surgery (CRS) followed by chemotherapy. In 1968
Munnell reported an improved survival in patients who
had maximal CRS compared to partial removal or biopsy
only [7] and over the years, many retrospective reports
have confirmed this finding [8-11]. Although no rand-
omized studies have been performed the role of surgery
was supported in a meta-analysis of 6885 patients under-
going CRS during the 'platinum era' where on an institu-
tional basis for each 10% increase in the percentage of
patients undergoing maximal CRS there was a 5.5%
increase in median survival duration [12].
The reason CRS is thought to be effective when combined
with chemotherapy is that it removes bulky disease con-
taining poorly-oxygenated, non-proliferating cells which
are either resistant to chemotherapy now, or potentially
could become resistant, and leaves small volume tumors
with a higher proportion of cells in the proliferative phase
making them more susceptible to chemotherapy. At one
time the concept of 'optimal' residual disease at comple-
tion of initial CRS for EOC was accepted as being any nod-
ule < 2 cm in dimension [13] but it is now established that
the most favorable prognosis is in patients with no mac-
roscopic residual disease at all [14]. Unfortunately, 'no
macroscopic disease' does not signify the complete
absence of disease because so many patients in this situa-
tion at the end of surgery experience recurrence following
front-line treatment. No less than 60% of patients who
present with advanced disease and have a complete path-
ologic response to front-line therapy documented at sec-
ond-look surgery will recur [15].
Chemotherapy
The most active chemotherapy agents in ovarian cancer
are the platinum analogues, cisplatin and carboplatin.
The antitumor activity of cisplatin (cis-diamminedichlo-
roplatinum (II)) was discovered by Rosenberg and col-
leagues in 1961 [16]. Initial studies demonstrated that the
whilst the agent had significant activity against several
tumor types patients experienced severe renal and gas-
trointestinal toxicity [17]. Later it was shown that renal
toxicity could be minimized by aggressive prehydration
and diuresis [18,19]. Cisplatin was introduced in the late
1970's and platinum-based combination chemotherapy
became the most frequently used treatment for EOC. In a
trial of single agent therapy, cisplatin was shown to be bet-
ter than a previously favored agent cyclophosphamide
[20]. Three major trials established cisplatin combination
therapy as the standard regimen in advanced EOC [21]. A
study randomizing patients with advanced EOC to cyclo-
phosphamide with or without cisplatin reported better
outcomes in the combination arm [22]. A Gynecologic
Oncology Group study which included over 200 patients
with advanced EOC reported that patients randomized to
treatment with doxorubicin and cyclophosphamide with
or without cisplatin had significantly better responses in
the cisplatin containing arm [23]. A Dutch study reported
a better outcome for a cisplatin containing regimen over
combination hexamethylmelamine, cyclophosphamide,
methotrexate, 5-fluorouracil (HexaCAF) [24]. The evi-
dence was further supported in a meta-analysis of 45 trials
including over 8000 patients with EOC treated with or
without cisplatin. Survival was better with platinum alone
and with platinum-containing combinations [25].
An additional class of drug, the taxanes, was discovered
and came to play a role in the front-line armamentarium
against EOC. In 1971 paclitaxel was identified as the
active constituent of an extract of the bark of the Pacific
yew tree, Taxus brevifolia [26,27]. In early clinical trials on
recurrent EOC paclitaxel was associated with an overall
response rate of 36% [28]. It became established as the
combination agent of choice with cisplatin after a Gyne-
cologic Oncology Group study in women with advanced,
suboptimally cytoreduced EOC showed a significantly
better median overall survival in patients randomized to
receive intravenous (IV) paclitaxel/cisplatin (37.5
months) in comparison with cyclophosphamide/cispla-
tin (24.4 months) [3]. Paclitaxel and subsequently its
cousin, docetaxel were shown to have a unique mecha-
nism of action binding to tubulin polymers (microtu-
bules) and stabilizing the microtubule against
depolymerization [29-32].
During this time analogues of cisplatin were investigated
in an effort to maintain efficacy with reduced toxicity. Car-
boplatin was developed by substituting a cyclobutanedi-
carboxylate moiety for the two chloride ligands of
cisplatin. Phase I and II trials of carboplatin showed that
it was much less toxic than cisplatin especially with regard
to neurotoxicity, nephrotoxicity and emetogenicity whilst
retaining significant chemotherapeutic activity [33-37].
Many trials have been performed comparing cisplatin and
carboplatin alone or in combination in patients with EOC
and two meta-analyses found no difference in survival
[25,38]. A large, randomized trial comparing intravenous
docetaxel with either cisplatin or carboplatin showed
equivalency [39] and following initial front-line CRS,
intravenous administration of cisplatin or carboplatin
together with a taxane, either paclitaxel or docetaxel, has
become the standard therapy for patients with EOC
[3,39].Page 2 of 7
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For over twenty years there has been interest in the deliv-
ery of intraperitoneal therapy for ovarian cancer in order
to maximize the efficacy and reduce the toxicity. Dedrick
proposed that the intraperitoneal delivery of certain
chemotherapeutic agents could lead to a significant
increase in peritoneal cavity drug exposure compared to
that in the systemic vascular compartment [40]. For drugs
most active in EOC the ratio of their intraperitoneal to
plasma concentrations varies from 18–20× for carbopla-
tin and cisplatin to 120 – > 1000× for the taxanes,
docetaxel and paclitaxel [41]. EOC should be a good tar-
get for intraperitoneal treatment because it is relatively
chemo-sensitive and the cancer remains confined within
the peritoneal cavity for much of its natural history. Three
large randomized studies [42-44] have each shown
improved responses for intraperitoneal (IP) delivery and
a meta-analysis of all studies reported a clear benefit for
patients receiving at least part of their front-line therapy
by the IP route [45]. A recent study (Gynecologic Oncol-
ogy Group protocol #172) examining experimental intra-
venous/intraperitoneal (IV/IP) chemotherapy for EOC
showed a significant increase in overall survival in those
receiving IP chemotherapy from 49 months to 66 months
[44]. The National Cancer Institute has suggested that IP
chemotherapy should be offered for patients' considera-
tion for front-line treatment of ovarian cancer [46].
Despite large randomized trials indicating benefit, the use
of intraperitoneal therapy in EOC is neither offered to the
majority of eligible women nor accepted as standard of
care by many oncologists
Despite the advances in the treatment of EOC much more
effective therapy is necessary. This is exemplified by the
results of Gynecologic Oncology Group protocol #172
where even in the IP/IV arm which led to median exten-
sion of survival of 16 months over patients treated only
with IV therapy the recurrence rate was 65% within the
period of the study. This recurrence rate is the current opti-
mum situation in EOC.
One way of improving outcome for patients with EOC is
to develop novel methods of enhancing the activity of cis-
platin. Ovarian cancers that are resistant to platinum ther-
apy are either innately resistant, shown by a lack of
response to front-line therapy, or develop platinum resist-
ance during the cancer's life history. In the patient this is
demonstrated by an initial response to platinum agents
followed by development of platinum resistance as the
cancer progresses. Most of the women die with platinum
resistant disease. Methods of preventing or overcoming
resistance to cisplatin thus could be extremely beneficial.
Cisplatin Resistance
Cisplatin reacts preferentially with the N7 position gua-
nine to form a variety of monofunctional and bifunc-
tional adducts which result in intrastrand or interstrand
cross-links, effectively preventing normal DNA function
[17,47]. Platinum resistance mechanisms fall into two
main groups: A) those that limit the formation of cyto-
toxic platinum-DNA adducts and B) those that prevent
cell death from occurring after platinum-DNA adduct for-
mation. Group A includes decreased drug accumulation
and increased drug inactivation by cellular protein and
non-protein thiols whilst Group B includes increased plat-
inum-DNA adduct repair and increased platinum-DNA
damage tolerance [17].
Cisplatin accumulates within the cell by passive diffusion
or facilitated transport [48] and the majority of cell lines
that have been selected for cisplatin resistance in vitro
show a decreased platinum accumulation phenotype
most likely due to decreased uptake rather than enhanced
drug efflux[17]. There are few experimental methods cur-
rently known to increase platinum uptake into cells but
one method is to deliver it with mild hyperthermia.
Hyperthermia has been shown to increase the cytotoxicity
of cisplatin and other chemotherapeutic agents in both
human cell culture and animal models [49-53]. Investiga-
tions of the cellular effects of the combination have dem-
onstrated increased DNA cross-linking and increased
DNA adduct formation [50,54]. It has also been shown
that cisplatin penetrates deeper into peritoneal tumor
implants when delivered intraperitoneally with hyper-
thermia [54]. The mechanism of the effect of hyperther-
mia on cisplatin cytotoxicity and the role it might play in
treatment awaits further investigation.
Multidrug resistance protein (MRP) is a member of a fam-
ily of transport proteins that facilitates the extrusion of a
variety of glutathione-coupled and unmodified drugs out
of cells but over-expression of MRP alone does not confer
resistance [55]. With regard to inactivation of platinum,
the formation of conjugates between glutathione (GSH)
and platinum drugs may be an important step for their
inactivation and elimination from the cell [17]. There is a
strong association between increased platinum drug sen-
sitivity and lower GSH levels [56]. However, reducing
GSH levels with drugs such as buthionine sulfoximine has
resulted in only low to modest potentiation of cisplatin
sensitivity [57]. It has been suggested that this may be due
to the fact that formation of GSH-platinum conjugates is
a slow process [58].
Inactivation may also occur by binding of the platinum
drugs to metallothionein (MT) proteins. MTs are a family
of sulfhydryl-rich, small molecular weight proteins that
participate in heavy metal binding and detoxication.
Modulation of MT levels can alter cisplatin sensitivity but
the contribution of MT to clinical platinum drug resist-
ance is unclear [17]. In some cell lines, elevated MT levelsPage 3 of 7
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ance, whereas in others, they have not [59,60].
Once platinum-DNA adducts are formed, cells must either
repair or tolerate the damage in order to survive. The
capacity to repair DNA damage rapidly and efficiently
plays a role in determining a tumor cell's sensitivity to
platinum drugs [17]. Increased repair of platinum-DNA
lesions in cisplatin-resistant cell lines has been compared
with their sensitive counterparts in several human cancer
cell lines, including ovarian cancer [61,62]. Repair of plat-
inum-DNA adducts occurs predominantly by nucleotide
excision repair (NER) [17].
Inhibiting DNA repair activity to enhance platinum drug
sensitivity has been an active area of investigation. Agents
that have been used include nucleoside analogues, such as
gemcitabine, fludarabine, and cytarabine; the riboncle-
otide reductase inhibitor hydroxyurea; and the inhibitor
of DNA polymerases alpha and gamma, aphidocolin. All
interfere with the repair synthesis stage of various repair
processes, including nucleotide excision repair. The
potentiation of cisplatin cytotoxicity by treatment with
aphidicolin has been studied extensively in human OC
cell lines with variable synergism [63-65]. The likelihood
of a significant improvement in the therapeutic index of
cisplatin in refractory patients by the coadministration of
a repair inhibitor is limited by the multifactorial nature
typical of resistant tumor cells.
Platinum-DNA damage tolerance is a phenotype that has
been observed in both cisplatin-resistant cells derived
from chemotherapy-refractory patients and cells selected
for primary cisplatin resistance in vitro. This phenotype
may result from alterations in a variety of cellular path-
ways. One component of DNA damage tolerance
observed in platinum-resistant cells involves loss of func-
tion of the DNA mismatch repair (MMR) system. The
main function of this is to scan newly synthesized DNA
and to remove mismatches that result from nucleotide
incorporation errors made by the DNA polymerases [17].
In addition to causing genomic instability, it has been
reported that loss of MMR is associated with low-level
platinum resistance.
Arsenic
Arsenic in its trivalent form is an interesting agent not
only with inherent tumoricidal activity [66] but having
multiple interactions that may enhance the cytotoxicity of
cisplatin. In particular, arsenic may inhibit DNA repair
[67], is clastogenic [68], induces stress response similar to
heat shock [69], binds with glutathione and is exported by
the multi-drug resistance protein MRP-1 [70], causes oxi-
dative stress [71,72] and can induce apoptosis [73-78].
One cellular defense mechanism against cisplatin is
dependent on glutathione conjugation and export by
(MRP-1) [79]. Since arsenite is exported from the cell by
the MRP-1 as a glutathione conjugate [70] it may compete
for MRP-1 and reduce the efficiency of cisplatin export
resulting in increased intracellular concentrations of cispl-
atin and the formation of more DNA adducts. Addition-
ally, arsenite induces a stress response with substantial
overlap with the heat shock induced stress response [69]
with many of the same proteins being induced, including
several heat shock proteins, heme-oxygenase and metal-
lothionein.
Arsenic has a long history of usage as a medicinal. In west-
ern medicine, arsenic was used to treat chronic myeloge-
nous leukemia until radiation treatment became
commonplace in the 1930's [80]. Interest in arsenic as a
chemotherapeutic was renewed when Chinese physicians
reported success in treating acute promyelocytic leukemia
(APL) with arsenic trioxide ("Pishi") also called "white
arsenic" or "arsenolite". Another form "Xionghuang" is
called "red arsenic" or "realgar" and realgar-containing
traditional medicines are used in cancer treatments such
as "Awei Huapi Gao" [81]. Arsenic trioxide (Trisenox®,
As2O3) is now an FDA (Federal Drug Administration)
approved chemotherapeutic for treating all-trans retinoic
acid (ATRA) resistant APL [82]. There is much interest in
the potential use of Trisenox® to treat other malignancies
(reviewed in [83,84]).
In vitro studies of arsenic trioxide induced cytotoxicity in
human ovarian cancer cells are promising. Clinically
achievable concentrations (2 μM) induced apoptosis in
the platinum-resistant human ovarian cancer cell line
CI80-13S and the platinum-sensitive human ovarian can-
cer cell line OVCAR. They also appeared to slow the
growth of the cisplatin-sensitive human ovarian cancer
cells GG and JAM [85]. Arsenic trioxide and cisplatin had
additive effects on human ovarian carcinoma MDAH2774
cells [86]. Growth was slowed but apoptosis was appar-
ently not induced in human ovarian carcinoma SKOV3
cells treated with arsenic trioxide in culture [87]. Arsenic
trioxide induced apoptosis in human ovarian cancer 3AO
cells and in a cisplatin-resistant derivative cell line 3AO/
CDDP was associated with a large increase in percentage
of cells expressing Fas [88]. These authors also reported
biphasic dose-dependent alterations in cell cycle with
increases in S-phase compartment associated with
decrease in G2/M compartment at low (< 1 μM) arsenic
trioxide and in G1 compartment at high (> 3 μM) arsenic
trioxide concentrations. Arsenic trioxide decreased perito-
neal metastasis of human ovarian cancer cells (3AO,
SW626, HO-8910PM) injected intraperitoneally into
nude mice, most likely because arsenic trioxide inhibited
matrix metalloproteinase MMP-2 and MMP-9 expressionPage 4 of 7
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shows some promise as a single agent in treating EOC.
Arsenic trioxide may be useful in combination therapy.
Polyunsaturated fatty acids appear to sensitize arsenic
resistant tumor cells, including SKOV3 cells, to arsenic tri-
oxide induced cytotoxicity and apoptosis [90]. There are
two reports examining combined exposure to arsenite and
cisplatin. One study with hepatocellular carcinoma cells
suggests that arsenite and cisplatin act synergistically [91].
Another study reported that arsenite exhibited additivity
with cisplatin, Adriamycin and etoposide in an ovarian
and two prostate cancer cell lines [86].
The preliminary studies of arsenic trioxide discussed
above suggest that arsenic trioxide may be useful in ther-
apy for EOC particularly in combination chemotherapy.
Consistent with this hypothesis is that preliminary studies
in our laboratories suggest that arsenic trioxide in combi-
nation with hyperthermia can overcome cisplatin resist-
ance in A2780/CP70 cells (manuscript in preparation).
Clearly, further study is warranted.
Conclusion
Despite modern standard therapy overall survival in
women with ovarian cancer remains relatively poor. The
most active chemotherapeutic agent remains cisplatin but
ironically most patients whilst initially responding to cis-
platin ultimately die with platinum-resistant disease.
Arsenic is a promising agent for helping overcome plati-
num resistance. In addition to inherent tumoricidal activ-
ity it has multiple biochemical interactions that may
enhance cisplatin cytotoxicity. Further research into this
agent is needed.
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